Careers  |  Sign In  |  Register

Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML

Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine compared to azacitidine monotherapy for the treatment of myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB AML). Dr. Sekeres explains that the primary endpoint of this trial was event-free survival (EFS), which favored the experimental combination over the azacitidine monotherapy at 21 months compared to 16.6 months, respectively, while each patient group showed distinct yet positive EFS duration over monotherapy.

Click here to learn more.